PDF
(Download)
|
- Cocoa (Theobroma cacao, Malvaceae)
- Flavan-3-ols
- Theobromine
- Cardiometabolic Risk Factors
|
Date:
03-13-2015 | HC# 021531-516
|
Re: Research Review Supports Cardioprotective Role of Cocoa
Berends
LM, van der Velpen V, Cassidy A. Flavan-3-ols, theobromine, and the effects of
cocoa and chocolate on cardiometabolic risk factors. Curr Opin Lipidol. 2015;26(1):10-19.
Potential
cardiovascular health benefits are attributed to cocoa (Theobroma cacao, Malvaceae) and chocolate through their bioactive
constituents, including polyphenols, stearic acid, and methylxanthines. This
review summarizes the recent research on the cardiometabolic effects of cocoa
and chocolate and focuses on two key bioactive constituents: flavan-3-ols and
theobromine. The main flavan-3-ols in chocolate are (–)-epicatechin,
(+)-catechin, and some of their oligomers, known as procyanidins. Theobromine
is another bioactive constituent of chocolate with potential beneficial health
effects. The role of chocolate in cardiovascular disease (CVD) has been studied
in both observational studies for cardiovascular endpoints and in randomized,
controlled trials (RCTs) for cardiometabolic markers.
In
a meta-analysis of six cohort studies and one cross-sectional study, a higher
chocolate intake was associated with a reduced risk for cardiometabolic
disorders.1 The greatest reductions were seen for CVD (37%) and
stroke (29%) in three studies. In one study, a reduction in diabetes was observed;
no effects of chocolate intake on heart failure were observed. A meta-analysis
of observational data showed an overall relative risk reduction of 19% for
stroke when comparing the highest and lowest categories of chocolate intake.2
Two other meta-analyses supported the association between chocolate intake and
reduced risk for CVD.
Three
meta-analyses of RCTs reviewed the impact of cocoa and chocolate consumption on
cardiometabolic health from short-duration studies (≤18 weeks). One reported a 2.77 mmHg decrease in
systolic blood pressure (SBP) and a 2.20 mmHg decrease in diastolic blood
pressure (DBP) after cocoa intake.3 Two of the meta-analyses
reported improved levels of both high-density lipoprotein cholesterol (HDL-C)
and low-density lipoprotein cholesterol (LDL-C) with cocoa consumption. In
another study, daily cocoa intake significantly improved HDL-C, glucose, and
several inflammatory biomarkers, but did not affect blood pressure, LDL-C, or
triglyceride concentrations.4
The
authors conclude that data from available RCTs on cardiometabolic markers
"largely support the findings on CVD outcomes in observational studies;
the short duration studies support potentially clinically relevant effects of
cocoa and chocolate on vascular function and insulin resistance."
Additional longer-term trials are needed.
According
to the authors, the most recent prospective cohort studies on flavan-3-ol
intake and cardiovascular health report no association with coronary heart
disease (CHD) mortality, CHD incidence, or stroke risk. One study of 98,469 men
and women over seven years, however, reported that higher flavan-3-ol intake
was associated with a 17% decrease in CVD mortality.5 Another study
of 1,063 women over five years reported a 66% decrease for atherosclerotic
vascular disease mortality associated with flavanol intake.6 A third
study of 7,172 subjects followed for more than four years reported a 60%
decrease in CVD events and mortality.7
Three
systematic reviews sought to determine the effective dose of flavan-3-ols. In
one, a nonlinear dose-response effect with a maximal effect was observed at a
total polyphenol intake of 500 mg. In another, intakes of epicatechin > 50
mg resulted in greater effects on SBP and DBP; flow-mediated dilatation (FMD)
improved at all levels of epicatechin intake.
The
authors conclude that "flavan-3-ols may mediate the beneficial effects of
cocoa and chocolate. However, in addition to elucidating the effective doses,
it remains to be established whether the flavan-3-ol monomers, their
phase-II-conjugated metabolites, the procyanidins or their gut metabolites are driving
any cardiometabolic effects."
Theobromine
may be responsible for mediating the observed beneficial effects of cocoa and
chocolate on lipoprotein levels, suggests a short-term RCT in which daily
consumption of theobromine (850 mg) for four weeks significantly increased
HDL-C concentrations.8 In another RCT, with a lower daily
consumption of theobromine (476 mg daily for four weeks), no changes were
reported in HDL-C levels.9 In some studies, high-dose theobromine
consumption was associated with gastrointestinal complaints, and acute
stimulatory effects on heart rate were observed following consumption of
500-1000 mg theobromine.
The
authors suggest further studies should investigate how theobromine affects
HDL-C functionality and cardiovascular health, along with the effects at
dietary-relevant levels, and its potential synergistic effects with other
bioactive compounds in chocolate.
The
authors conclude, "Evidence for a cardioprotective role of chocolate
consumption is apparent from the population-based studies and short-term RCTs,
and currently provides greater support for the flavan-3-ol content rather than
theobromine. However, interpretation of findings is difficult because of considerable
variability between studies and it is unclear whether they work individually or
in synergy."
—Shari Henson
References
1Buitrago-Lopez A,
Sanderson J, Johnson L, et al. Chocolate consumption and cardiometabolic
disorders: systematic review and meta-analysis. BMJ. 2011;343:d4488. doi: 10.1136/bmj.d4488.
2Larsson SC, Virtamo J,
Wolk A. Chocolate consumption and risk of stroke: a prospective cohort of men
and meta-analysis. Neurology.
2012;79(12):1223-1229.
3Ried K, Sullivan TR,
Fakler P, Frank OR, Stocks NP. Effect of cocoa on blood pressure. Cochrane Database Syst Rev.
2012;8:CD008893. doi: 10.1002/14651858.CD008893.pub2.
4Sarriá B, Martínez-López
S, Sierra-Cinos JL, García-Diz L, Mateos R, Bravo L. Regular consumption of a
cocoa product improves the cardiometabolic profile in healthy and moderately
hypercholesterolaemic adults. Br J Nutr.
2014;111(1):122-134.
5McCullough ML,
Peterson JJ, Patel R, Jacques PF, Shah R, Dwyer JT. Flavonoid intake and
cardiovascular disease mortality in a prospective cohort of US adults. Am J Clin Nutr. 2012;95(2):454-464.
6Ivey KL, Lewis JR,
Prince RL, Hodgson JM. Tea and non-tea flavonol [sic] intakes in relation to atherosclerotic vascular disease
mortality in older women. Br J Nutr.
2013;110(9):1648-1655.
7Tresserra-Rimbau A,
Medina-Remón A, Pérez-Jiménez J, et al. Dietary intake and major food sources
of polyphenols in a Spanish population at high cardiovascular risk: the
PREDIMED study. Nutr Metab Cardiovasc Dis.
2013;23(10):953-959.
8Neufingerl N, Zebregs
YE, Schuring EA, Trautwein EA. Effect of cocoa and theobromine consumption on
serum HDL-cholesterol concentrations: a randomized controlled trial. Am J Clin Nutr. 2013;97(6):1201-1209.
9West SG, McIntyre MD,
Piotrowski MJ, et al. Effects of dark chocolate and cocoa consumption on
endothelial function and arterial stiffness in overweight adults. Br J Nutr. 2014;111(4):653-661.
|